Press releases and news
2022
2021 and 2020 Lipid Science Prize awarded to inventors of m-RNA and lipid nanoparticle technologies
Camurus’ Full Year Report 2021
Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
2021
Change in number of shares and votes in Camurus
Braeburn receives new Complete Response Letter for Brixadi in the US
The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus’ Interim Report Third Quarter 2021
Camurus’ Nomination Committee appointed for the Annual General Meeting 2022
Camurus appoints Jon U. Garay Alonso as Chief Financial Officer
Change in number of shares and votes in Camurus
FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease
Camurus’ Chief Financial Officer (CFO) will leave the company
Change in number of shares and votes in Camurus
Camurus’ Interim Report Second Quarter 2021
Change in number of shares and votes in Camurus
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
Change in number of shares and votes in Camurus
Exercise of Camurus’ subscription warrant program 2018/2021
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.